Author:
Karner Charlotta,Kew Kayleigh,Wakefield Victoria,Masento Natalie,Edwards Steven J
Abstract
ObjectiveTo compare the effectiveness and safety of treatments for advanced or metastatic renal cell carcinoma (amRCC) after treatment with vascular endothelial growth factor (VEGF)-targeted treatment.DesignSystematic review and network meta-analysis of randomised controlled trials (RCTs) and comparative observational studies. MEDLINE, EMBASE and Cochrane Library were searched up to January 2018.ParticipantsPeople with amRCC requiring treatment after VEGF-targeted treatment.InterventionsAxitinib, cabozantinib, everolimus, lenvatinib with everolimus, nivolumab, sorafenib and best supportive care (BSC).OutcomesPrimary outcomes were overall survival (OS) and progression-free survival (PFS); secondary outcomes were objective response rate (ORR), adverse events, and health-related quality of life (HRQoL).ResultsTwelve studies were included (n=5144): five RCTs and seven observational studies. Lenvatinib with everolimus significantly increased OS and PFS over everolimus (HR 0.61, 95% Credible Interval [95%CrI]: 0.36 to 0.96 and 0.47, 95%CrI: 0.26 to 0.77, respectively) as did cabozantinib (HR 0.66, 95%CrI: 0.53 to 0.82 and 0.51, 95%CrI: 0.41 to 0.63, respectively). This remained the case when observational evidence was included. Nivolumab also significantly improved OS versus everolimus (HR 0.74, 95%CrI: 0.57 to 0.93). OS sensitivity analysis, including observational studies, indicates everolimus being more effective than axitinib and sorafenib. However, inconsistency was identified in the OS sensitivity analysis. PFS sensitivity analysis suggests axitinib is more effective than everolimus, which may be more effective than sorafenib. The results for ORR supported the OS and PFS analyses. Nivolumab is associated with fewer grade 3 or grade 4 adverse events than lenvatinib with everolimus or cabozantinib. HRQoL could not be analysed due to differences in tools used.ConclusionsLenvatinib with everolimus, cabozantinib and nivolumab are effective in prolonging the survival for people with amRCC subsequent to VEGF-targeted treatment, but there is considerable uncertainty about how they compare to each other and how much better they are than axitinib and sorafenib.PROSPERO registrationnumberCRD42017071540.
Funder
Health Technology Assessment Programme
Reference41 articles.
1. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
2. Cancer Research UK (CRUK). Kidney cancer statistics. 2015. Available at http://wwwcancerresearchukorg/health-professional/cancer-statistics/statistics-by-cancer-type/kidney-cancer#heading-Zero (Accessed: 10 Mar 2016).
3. European Medicines Agency (EMA). Sutent (sunitinib) European public assessment report (EPAR). 2007 https://www.ema.europa.eu/documents/overview/sutent-epar-summary-public_en.pdf (accessed: 14 Nov 2018).
4. European Medicines Agency (EMA). Nexavar (sorafenib) European public assessment report (EPAR). 2009 https://www.ema.europa.eu/documents/overview/nexavar-epar-summary-public_en.pdf (accessed: 14 Nov 2018).
5. European Medicines Agency (EMA). Afinitor (everolimus) European public assessment report (EPAR). 2010 https://www.ema.europa.eu/documents/overview/afinitor-epar-summary-public_en.pdf (accessed: 14 Nov 2018).
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献